Phytotherapy has been used to treat a different type of diseases including
cancer for a long time, and it was a source for different active anti-
tumor agents. Oncolytic Newcastle disease virus (AMHA1) are very promising anti-
tumor therapy. Nevertheless, NDV-based monotherapeutics have not been very useful to some resistant
tumors. Thus, the efficiency of oncolytic NDV must enhance by combining NDV with other novel
therapies. The current study aimed to determine the possibility of improving the oncolytic effect induced by NDV through Rheum ribes rhizomes extract administration in vitro and in vivo. Methods, the in vitro study include exposure of the
crude extract of Rheum ribes alone or NDV alone or combination of both agents for 72 h. The
cancer cells tested were murine mammary
adenocarcinoma AMN3, Human
Rhabdomyosarcoma RD, and Human
Glioblastoma AMGM5, and using rat embryo fibroblast REF as normal control cells. MTT cell viability assay was used and analyzed for possible synergism using the Chou-Talalay analysis method. In vivo experiment included study the combination and the monotherapeutic modalities in the transplanted murine mammary
adenocarcinoma AM3 line and
tumor sections analyzed by histopathology. Results, Combination
therapy of NDV-R. ribes showed enhanced oncolytic activity on
cancer cells. With no cytotoxicity on normal cells. In vivo study showed that monotherapeutic modalities had lower growth inhibitory effect on transplanted
tumors in mice in compare to combination
therapy. Histopathological examination revealed the broader area of
necrosis in
tumors treated by combination
therapy. In conclusion, the novel combination recommended for clinical application for
cancer therapy.